Additional Preclinical Trial Data to Be Presented at the 2012 Experimental Biology Conference
SOUTH SAN FRANCISCO, CA, Apr 18, 2012 (MARKETWIRE via COMTEX) --Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that one
oral presentation and two poster presentations are scheduled to be
presented at the 64th Annual Meeting of the American Academy of
Neurology, to be held April 21-28, 2012 in New Orleans, LA. In
addition, a poster presentation containing preclinical data relating
to CK-2017357 is scheduled to be presented at the 2012 Experimental
Biology Conference being held April 21-25, 2012 in San Diego, CA.
CK-2017357 is the lead drug candidate that has emerged from the
company's skeletal muscle contractility program. CK-2017357
selectively activates the fast skeletal muscle troponin complex by
increasing its sensitivity to calcium, which increases skeletal
muscle force in response to neuronal input and delays the onset and
reduces the degree of muscle fatigue.
Oral Presentation at the 64th Annual Meeting of the American Academy
of Neurology
Date: Wednesday, April 25, 2012
Presentation Time: 2:00 PM - 3:45 PM
Central Daylight Time
Presentation #: S25.005
Session: S25:
Anterior Horn
Title: A Study to Evaluate Safety, and Tolerability of
Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic
Lateral Sclerosis
Presenter: Jeremy M. Shefner, MD, PhD, Professor
and Chair, Department of Neurology at the Upstate Medical University,
State University of New York
Poster Presentation at the 64th Annual Meeting of the American
Academy of Neurology
Date: Wednesday, April 25, 2012
Presentation Time: 7:30 AM - 9:00 AM
Central Daylight Time (poster displayed 7:30 AM - 12:00 PM)
Poster
#: P04.155
Session: P04: Anterior Horn: Therapeutics
Title: A Study
to Evaluate Safety and Tolerability of CK-2017357 (CK-357) in
Patients with Amyotrophic Lateral Sclerosis Using a Twice-Daily,
Dose-Titration Regimen
Presenter: Jeremy M. Shefner, MD, PhD,
Professor and Chair, Department of Neurology at the Upstate Medical
University, State University of New York
Date: Wednesday, April 25, 2012
Presentation Time: 5:30 PM - 7:00 PM
Central Daylight Time (poster displayed 2:00 PM - 7:00 PM)
Poster #:
P05.169
Session: P05: Anterior Horn: Basic Science
Title: The Fast
Skeletal Troponin Activator, CK-2017357, Increases Muscle Function
and Survival in SOD1 (G93A) Mice; a Model of ALS
Presenter: Fady I.
Malik, MD, PhD, FACC, Cytokinetics, South San Francisco, CA
Poster Presentation at 2012 Experimental Biology Conference:
Date: Wednesday, April 25, 2012
Presentation Time: 12:30 PM - 2:45
PM Pacific Daylight Time (poster displayed 7:30 AM - 5:30 PM)
Abstract #: S85 1121.7
Title: The Fast Skeletal Troponin Activator,
CK-2017357, Improves Resistance to Fatigue in Healthy, Conscious Rats
Presenter: Adam R. Kennedy, PhD, Cytokinetics, South San Francisco,
CA
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on
the discovery and development of novel small molecule therapeutics
that modulate muscle function for the potential treatment of serious
diseases and medical conditions. Cytokinetics' lead drug candidate
from its cardiac muscle contractility program, omecamtiv mecarbil, is
in Phase II clinical development for the potential treatment of heart
failure. Amgen Inc. holds an exclusive license worldwide (excluding
Japan) to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and
commercialization participation rights. Cytokinetics is independently
developing CK-2017357, a skeletal muscle activator, as a potential
treatment for diseases and conditions associated with aging, muscle
wasting or neuromuscular dysfunction. CK-2017357 is currently the
subject of a Phase II clinical trials program and has been granted
orphan drug designation by the U.S. Food and Drug Administration and
orphan medicinal product designation by the European Medicines Agency
for the potential treatment of amyotrophic lateral sclerosis, a
debilitating disease of neuromuscular impairment in which CK-2017357
demonstrated potentially clinically relevant pharmacodynamic effects
in a Phase IIa trial. Cytokinetics is also conducting research of
compounds that inhibit smooth muscle contractility and which may be
useful as potential treatments for diseases and conditions associated
with excessive smooth muscle contraction, such as bronchoconstriction
associated with asthma and chronic obstructive pulmonary disorder
(COPD). All of these drug candidates and potential drug candidates
have arisen from Cytokinetics' research activities and are directed
towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes
of the Private Securities Litigation Reform Act of 1995 (the "Act").
Cytokinetics disclaims any intent or obligation to update these
forward-looking statements, and claims the protection of the Act's
safe harbor for forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
planned presentations, and the properties and potential benefits of
Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, potential difficulties or delays in
the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval,
including risks that current and past results of clinical trials or
preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
Contact:
Jodi L. Goldstein
Manager, IR, Corporate Communications & Marketing
(650) 624-3000
SOURCE: Cytokinetics, Inc.
